Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04497779 · ClinicalTrials.gov registry record

Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma

A clinical trial of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed, sponsored by City of Hope Medical Center.

Active
Registry status
95
Enrollment target
1
Study location

NCT04497779 is a study of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 95 participants, above the 37-participant average among 3 other Symptomatic COVID-19 Infection Laboratory-Confirmed trials with a reported enrollment target (157% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04497779, a study of Symptomatic COVID-19 Infection Laboratory-Confirmed and Asymptomatic COVID-19 Infection Laboratory-Confirmed, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
95 participants
Enrollment target
1
Study location

Study Summary

Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • OTHER Electronic Health Record Review
  • OTHER Diagnostic Laboratory Biomarker Analysis

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2020-07-13
Est. Completion 2026-10-13

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT04497779

The ClinicalTrials.gov registry entry for NCT04497779 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 3 other Symptomatic COVID-19 Infection Laboratory-Confirmed trials with a reported enrollment target (157% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Symptomatic COVID-19 Infection Laboratory-Confirmed appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT04497779 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04497779 about?

NCT04497779 is a clinical study titled "Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma". Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID...

What is the current status of trial NCT04497779?

This trial is currently active not recruiting. The enrollment target is 95 participants. The study started on 2020-07-13. Estimated completion is 2026-10-13.

What conditions does trial NCT04497779 study?

This clinical trial studies the following conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed, Asymptomatic COVID-19 Infection Laboratory-Confirmed.

What interventions are being tested in trial NCT04497779?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER), Diagnostic Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT04497779?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04497779 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Symptomatic COVID-19 Infection Laboratory-Confirmed

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.